GILD News 93.98 08/14/2014 05:10:19 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 93.98 $GILD

Final Glance: Biotechnology companies
AP - Wed Aug 13, 5:14PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:

Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.

Midday Glance: Biotechnology companies
AP - Wed Aug 13, 12:50PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:

BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:02PM CDT
Shares of BioDelivery Sciences International, Inc. (BDSI) jumped 7.58 % after the company reported its second-quarter 2014 results.

Pharmacyclics Has Edge Over Blood Cancer Competitors
at The Street - Wed Aug 13, 9:49AM CDT
Imbruvica will be an important part of the treatment landscape for blood cancers.

Intercept Pharmaceuticals Posts Earnings, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 9:40AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) reported earnings of $1.51 per share in the quarter comparing favorably with the Zacks Consensus estimate of a loss of $1.10.

Early Glance: Biotechnology companies
AP - Wed Aug 13, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:

Gilead Sciences,Melco Crown Entertainment,Banco Santander, BarclaysandDeutsche Bankhighlighted as Zacks Bull and Bear of the Day
PR Newswire - Wed Aug 13, 8:30AM CDT
Zacks Equity Research highlights Gilead Sciences (Nasdaq:GILD-Free Report) as the Bull of the Day and Melco Crown Entertainment (Nasdaq:MPEL-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onBanco Santander, S.A. (NYSE:SAN-Free Report), Barclays PLC (NYSE:BCS-Free Report) and Deutsche Bank AG (NYSEB-Free Report).

Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Aug 13, 7:30AM CDT
Celladon stock fell over 6% last trading session, continuing its recent downtrend

Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - ZACKS - Wed Aug 13, 2:06AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day

Apple, Facebook Among 5 Top Rated Big Cap Stocks
at Investor's Business Daily - Tue Aug 12, 7:35PM CDT
Stability is a critical determination in picking stock-watch candidates when the market is in correction. Today's Screen Of The Day is Big Cap Leaders, companies with top-notch fundamentals and a market capitalization of at least $15 billion. The...

Regeneron's Eye Drug Eylea Cleared in the EU for DME - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 4:20PM CDT
Regeneron's (REGN) Eylea has been approved for a third indication in the EU.

Tekmira Shares Continue to Rise in the Search for Ebola Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 3:20PM CDT
Shares of Tekmira (TKMR) rose for the second successive day following the FDA announcement on TKM-Ebola.

Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:49PM CDT
Sarepta reported second quarter loss of 85 cents per share compared to a loss of 60 cents per share in the year-ago quarter.

Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:30AM CDT
Spectrum Pharmaceuticals (SPPI) reported second-quarter 2014 earnings of 16 cents per share, compared to the year-ago loss of 15 cents.

MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 10:05AM CDT
MannKind's (MNKD) loss of 19 cents per share was wider than the Zacks Consensus Estimate of a loss of 11 cents

Intercept Pharma Soars On Liver-Disease Drug Data
at Investor's Business Daily - Tue Aug 12, 9:48AM CDT
Biotech Intercept Pharmaceuticals (ICPT) was riding high on an upgrade and multiple price-target increases after it issued new data late Monday on its fatty-liver-disease drug candidate. Intercept Pharma stock vaulted 31% in early trading on the...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 116

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 37

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 32

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 90

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 83

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 114

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading

Top 5 Most Recently Viewed Articles

Immuron Advances IMM-529 Development Following FDA Feedback

Updated Category News Views 289

Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.

Continue Reading
Enefit Green to Host Webinars for Unveiling 2024 Results

Updated Category News Views 123

Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...

Continue Reading
Intapp's Encouraging Earnings Fuel Stock Surge Amid Market Momentum

Updated Category News Views 197

Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...

Continue Reading
NewAmsterdam Pharma's Upcoming Conference Participation for 2024

Updated Category News Views 229

NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...

Continue Reading
John Hancock Funds Announce Monthly Distribution Updates

Updated Category News Views 366

Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...

Continue Reading